The clinical features of combined central and peripheral demyelination and antibodies against the node of Ranvier

Abstract

Background:

Combined central and peripheral demyelination (CCPD) is a disease of inflammatory demyelination that affects central and peripheral nerves simultaneously or temporally separated.

Objectives:

This study evaluated the clinical characteristics and the existence of antinodal/paranodal antibodies in patients with CCPD.

Methods:

We reviewed the clinical manifestations, laboratory tests, electrophysiological examinations, neuroimaging findings, treatment, and prognosis of 31 patients with CCPD. Using a live cell–based assay, we tested antinodal/paranodal antibodies.

Results:

The most common symptoms were motor weakness (83.3%), hyporeflexia (63.3%), and sphincter disturbance (58.1%). In total, 16.6% of patients had impaired vision symptoms, whereas 33.3% of patients had abnormal visual-evoked potentials (VEPs). A total of 21.1% (4/19) of patients were positive for anti-AQP4 (aquaporin 4) antibodies, 20.0% (2/10) of patients were positive for anti-NF155 (neurofascin-155) antibodies, and 10.0% (1/10) of patients were positive for anti-MAG (myelin-associated glycoprotein) antibodies. The effective rates of intravenous corticosteroids, intravenous immunoglobulins, and rituximab were 72.2%, 37.5%, and 100%, respectively. At the illness peak, 75% of patients with CCPD had an mRS (modified Rankin Scale) score of 4 or greater. In remission, 37.5% had an mRS score of 4 or greater.

Conclusion:

The clinical manifestations of patients with CCPD are highly heterogeneous. We recommend testing antinodal/paranodal antibodies for patients with CCPD.

Keywords

Combined central and peripheral demyelination neurofascin myelin-associated glycoprotein inflammatory demyelinating disease antibodies

Get full access to this article

View all access options for this article.

References

Thomas

Walker

Rudge

, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 1987; 110(1): 53–76.

Zephir

Stojkovic

Latour

, et al. Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 2008; 79(9): 1032–1039.

Kawamura

Yamasaki

Yonekawa

, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013; 81(8): 714–722.

Cortese

Franciotta

Alfonsi

, et al. Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment. J Neurol Sci 2016; 363: 182–187.

Ogata

Matsuse

Yamasaki

, et al. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry 2016; 87(1): 29–36.

Wang

Chen

Zhuang

, et al. The clinical features of combined central and peripheral demyelination in Chinese patients. J Neuroimmunol 2018; 317: 32–36.

Vural

Göçmen

Kurne

, et al. Fulminant central plus peripheral nervous system demyelination without antibodies to neurofascin. Can J Neurol Sci 2016; 43(1): 149–156.

Reindl

Schanda

Woodhall

, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020; 7(2): e674.

Irani

Alexander

Waters

, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010; 133(9): 2734–2748.

10.

Rubin

Karpati

Carpenter

. Combined central and peripheral myelinopathy. Neurology 1987; 37(8): 1287–1290.

11.

Mendell

Kolkin

Kissel

, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987; 37(8): 1291–1294.

12.

Krivickas

Hochberg

Freeman

. Chronic inflammatory demyelinating polyradiculoneuropathy with tumefactive central demyelination. Muscle Nerve 2006; 33(2): 283–288.

13.

Adamovic

Riou

Bernard

, et al. Acute combined central and peripheral nervous system demyelination in children. Pediatr Neurol 2008; 39(5): 307–316.

14.

Dobson

Ramagopalan

Davis

, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: A meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84(8): 909–914.

15.

Vural

Göçmen

Kurne

, et al. Fulminant central plus peripheral nervous system demyelination without antibodies to neurofascin. Can J Neurol Sci 2016; 43(1): 149–156.

16.

Cortese

Devaux

Zardini

, et al. Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurol Neuroimmunol Neuroinflamm 2016; 3(4): e238.

17.

Kira

Yamasaki

Ogata

. Anti-neurofascin autoantibody and demyelination. Neurochem Int 2019; 130: 104360.

18.

Boscarino

Lanzone

Ricci

, et al. Spinal cord impairment in anti-MAG neuropathy: Evidence from somatosensory evoked potentials. Brain Sci 2020; 10(5): 282.

19.

Zis

Rao

Hoggard

, et al. Anti-MAG associated cerebellar ataxia and response to rituximab. J Neurol 2018; 265(1): 115–118.

20.

Sotgiu

Giua

Murrighile

, et al. A case of anti-myelin-associated glycoprotein polyneuropathy and multiple sclerosis: One disease instead of two. BMJ Case Rep 2009; 2009: bcr06.

21.

Rinaldi

Davies

Fehmi

, et al. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 2021; 8(1): 0924.

22.

Ueno

Kinoshita

Arai

, et al. Combined central and peripheral demyelination with tumefactive demyelinating lesions in the brainstem and longitudinally extensive optic neuritis: A case report. Neurol Sci 2020; 41: 1601–1603.

23.

Mizuno

Shinoda

Watanabe

, et al. Intractable axonal neuropathy with multifocal peripheral nerve swelling in neuromyelitis optica spectrum disorders: A case report. Mult Scler Relat Disord 2019; 35: 16–18.

24.

Vazquez

Campo

Stephens

Marin Collazo

, et al. MOG antibodies in combined central and peripheral demyelination syndromes. Neurol Neuroimmunol Neuroinflamm 2018; 5(6): e503.

25.

Takai

Misu

Nakashima

, et al. Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology 2012; 79(17): 1826–1828.

26.

Nakamura

Kaneko

Watanabe

, et al. Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. Neurol Sci 2021; 42: 1135–1138.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB